Boill Healthcare Holdings Limited provided Group earning guidance for the financial year ended 31 March 2022. The Group is expected to record a consolidated net loss of not less than approximately HKD 790 million for the Year, as compared with the consolidated net loss of approximately HKD 175 million for the year ended 31 March 2021. Such expected substantial consolidated net loss for the Year was mainly due to the following factors: the expected fair value loss on investment properties of approximately HKD 592 million for the Year (2021: approximately HKD 4 million) and expected impairment loss on property, plant and equipment of approximately HKD 61 million for the Year (2021: reversal of impairment loss of approximately HKD 5 million) due to the adverse impact caused by the outbreak of COVID-19 pandemic and the weakened demand of potential home-buying customers due to deterioration of their overall financial condition brought by the uncertain global macro-economic environment; and (ii) the increase in income tax and land appreciation tax of approximately HKD 28 million provided for the Year (2021: income tax credit of approximately HKD 5 million) as a result of the increase in delivery of properties.